| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 137, 1121-1142, Copyright © 1990 by American Society for Investigative Pathology
REGULAR ARTICLES |
SS Brem, D Zagzag, AM Tsanaclis, S Gately, MP Elkouby and SE Brien
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.
Microvascular proliferation, a hallmark of malignant brain tumors, represents an attractive target of anticancer research, especially because of the quiescent nonproliferative endothelium of the normal brain. Cerebral neoplasms sequester copper, a trace metal that modulates angiogenesis. Using a rabbit brain tumor model, normocupremic animals developed large vascularized VX2 carcinomas. By contrast, small, circumscribed, relatively avascular tumors were found in the brains of rabbits copper-depleted by diet and penicillamine treatment (CDPT). The CDPT rabbits showed a significant decrease in serum copper, copper staining of tumor cell nuclei, microvascular density, the tumor volume, endothelial cell turnover, and an increase in the vascular permeability (breakdown of the blood-brain barrier), as well as peritumoral brain edema. In non-tumor-bearing animals, CDPT did not alter the vascular permeability or the brain water content. CDPT also inhibited the intracerebral growth of the 9L gliosarcoma in F-344 rats, with a similar increase of the peritumoral vascular permeability and the brain water content. CDPT failed to inhibit tumor growth and the vascularization of the VX2 carcinoma in the thigh muscle or the metastases to the lung, findings that may reflect regional differences in the responsiveness of the endothelium, the distribution of copper, or the activity of cuproenzymes. Metabolic and pharmacologic withdrawal of copper suppresses intracerebral tumor angiogenesis; angiosuppression is a novel biologic response modifier for the in situ control of tumor growth in the brain.
This article has been cited by other articles:
 |
|
 |
|
  S. A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S. M. Watt, S. Joel, F. Donate, C. Hayward, S. Reich, et al. Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7526 - 7534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brem, S. A. Grossman, K. A. Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy CNS Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma Neuro-oncol, July 1, 2005; 7(3): 246 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Elner, V. M. Elner, A. Yoshida, R. D. Dick, and G. J. Brewer Effects of Tetrathiomolybdate in a Mouse Model of Retinal Neovascularization Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 299 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wallace Integrative Tumor Board: Glioblastoma Multiforme: Nutritional and Botanical Approach Integr Cancer Ther, June 1, 2004; 3(2): 152 - 163. [PDF]
|
|
|
|
 |
|
 C. Cox, S. D. Merajver, S. Yoo, R. D. Dick, G. J. Brewer, J. S.-J. Lee, and T. N. Teknos Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Suppression in a Murine Model Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 781 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Redman, P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer, and S. D. Merajver Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1666 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Brewer and S. D. Merajver Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper--A Review Integr Cancer Ther, December 1, 2002; 1(4): 327 - 337. [Abstract] [PDF]
|
|
|
|
 |
|
 Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, et al. Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis Cancer Res., September 1, 2002; 62(17): 4854 - 4859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Brewer Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease Experimental Biology and Medicine, July 1, 2001; 226(7): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shiose, T. Sakamoto, H. Yoshikawa, Y. Hata, Y. Kawano, T. Ishibashi, H. Inomata, K. Takayama, and H. Ueno Gene Transfer of a Soluble Receptor of VEGF Inhibits the Growth of Experimental Eyelid Malignant Melanoma Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2395 - 2403. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Brewer, R. D. Dick, D. K. Grover, V. LeClaire, M. Tseng, M. Wicha, K. Pienta, B. G. Redman, T. Jahan, V. K. Sondak, et al. Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study Clin. Cancer Res., January 1, 2000; 6(1): 1 - 10. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Gately, P. Twardowski, M. S. Stack, D. L. Cundiff, D. Grella, F. J. Castellino, J. Enghild, H. C. Kwaan, F. Lee, R. A. Kramer, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin PNAS, September 30, 1997; 94(20): 10868 - 10872. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
